TAVAD Ultra-Rapid Detoxification of Opiates Allows for Successful Rehabilitation in 7 out of 10 Patients

MADRID, September 8, 2015 /PRNewswire/ --

According to the Annual Results' Report on the treatment of ultra-rapid detoxification of opiates undertaken by the Spanish drug treatment center TAVAD, the clinical profile of patients with dependency on this substance tends to be male, single and aged around 30 years with an on-going history of heroin or methadone consumption lasting for around 7 years.  

The Annual Results' Report presented yearly by the TAVAD (Advanced Addiction Treatments) drug treatment center, offers some highly positive data. Of the total number of patients who underwent TAVAD programmes last year for opiate dependency (such as heroin or methadone), 100% of them completed the detoxification programme successfully, and 73% of the aforesaid total have continued to evolve in a positive manner one year since discharge from hospital.

     (Logo: http://photos.prnewswire.com/prnh/20150723/240726LOGO )

TAVAD performs an ultra-rapid detoxification of opiates, carried out under deep sedation and lasting for approximately 8 hours. During this time, an advanced pharmacological intervention is performed which will be pivotal in the patient's recovery: neuro-regulation. "During this procedure, the recovery of cerebral structures altered by the consumption of opiates takes place. This pharmacological intervention is of great significance, as it means that advanced processes of cognition and affection are restored, along with one's attention span, reading ability, awareness or serenity which  foster psychotherapy and rehabilitation," indicates Dr. Legarda, the Head of the Center and creator of this advanced method of treating addictions.

Following the stay in hospital which never exceeds 72 hours, the second phase of the treatment begins whereby the patient is accompanied in their rehabilitation with medical, psychological, and pharmacological support for one year.

For more than 20 years, research performed at TAVAD in clinical matters has been geared towards improving the results of its treatments and the development of new clinical procedures to accomplish the wellbeing and recovery of patients admitted to the centre. Since the publication of its first set of results in 1998, in tandem with the Agency for the Evaluation of Healthcare Technology of the Carlos III Health Institute, TAVAD has made all the data obtained regarding the treatments available to researchers, scientific and clinical staff on the web page of this drug treatment center.

More information:
http://www.tavad.com/
Dr. Legarda: +34-91-3161377
[email protected]

SOURCE TAVAD